| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB120-6405SS | |||
| Azide and BSA Free | NBP2-80848 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-77080SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-76701SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB100-64775-0.05mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| IHC-Prediluted | NBP2-44513 | |||
| Azide and BSA Free | NBP2-34569-0.1mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-22115SS | |||
| Azide and BSA Free | NBP2-80618 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-65805SS | |||
| Azide and BSA Free | NBP2-80660 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-97728SS | |||
| Azide and BSA Free | NBP2-33253 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-07035SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-40686-0.025mg | |||
![Immunohistochemistry-Paraffin: CCR7 Antibody [NB100-712] - M1 and M2 macrophages showed similar expression patterns in cortical bone. IHC staining was performed in sagittal serial sections of medial condyles from 6-week-old rats within the diaphyseal region. Cluster of differentiation 68 (CD68) was selected as a pan marker for the macrophage lineage, including monocytes, macrophages, giant cells, and osteoclasts. iNOS and C-C chemokine receptor type 7 (CCR7) were selected as M1 phenotypic markers, whereas Arginase1 and cluster of differentiation 163 (CD163) were selected as M2 phenotypic markers. Tartrate-resistant acid phosphatase (TRAP) staining was performed as described in Materials and Methods. Quantification of cell numbers according to their location revealed that most of the M1 and M2 cells were not attached to the bone surfaces. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/boneres201719) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCR7-Antibody-Immunohistochemistry-Paraffin-NB100-712-img0006.jpg "Immunohistochemistry-Paraffin: CCR7 Antibody [NB100-712] - M1 and M2 macrophages showed similar expression patterns in cortical bone. IHC staining was performed in sagittal serial sections of medial condyles from 6-week-old rats within the diaphyseal region. Cluster of differentiation 68 (CD68) was selected as a pan marker for the macrophage lineage, including monocytes, macrophages, giant cells, and osteoclasts. iNOS and C-C chemokine receptor type 7 (CCR7) were selected as M1 phenotypic markers, whereas Arginase1 and cluster of differentiation 163 (CD163) were selected as M2 phenotypic markers. Tartrate-resistant acid phosphatase (TRAP) staining was performed as described in Materials and Methods. Quantification of cell numbers according to their location revealed that most of the M1 and M2 cells were not attached to the bone surfaces. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/boneres201719) licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: CCR7 Antibody [NB100-712] - Mouse spleen](http://images.novusbio.com/fullsize/CCR7-Antibody-Immunohistochemistry-Paraffin-NB100-712-img0001.jpg)
![Immunohistochemistry-Paraffin: CCR7 Antibody [NB100-712] - Mouse spleen](http://images.novusbio.com/fullsize/CCR7-Antibody-Immunohistochemistry-Paraffin-NB100-712-img0004.jpg)
![Immunohistochemistry-Paraffin: CCR7 Antibody [NB100-712] - Human spleen](http://images.novusbio.com/fullsize/CCR7-Antibody-Immunohistochemistry-Paraffin-NB100-712-img0005.jpg)
![Immunohistochemistry: CCR7 Antibody [NB100-712] - M1 expression pattern changed in trabecular bone. Immunohistochemical staining was performed in sagittal serial sections of medial condyles from 6-week-old rats within the epiphyseal region. The region with the solid line indicates areas of interest to be enlarged in the following image. Representative staining with the anticluster of differentiation 68 (CD68) antibody demonstrated that CD68+ cells were either attached (black arrows) or unattached (white arrows) to the bone surfaces with a variety of sizes & shapes (a, b). TRAP+ cells showed multinucleated morphology (black arrows) which is similar to the CD68+ cells (c, d). Inducible nitric oxide synthase-positive (iNOS+) & C-C chemokine receptor type 7-positive (CCR7+) cells (black arrow) were attached to the bone surfaces with an elongated morphology (e, f, i, j). Arginase1+ & cluster of differentiation 163-positive (CD163+) cells (white arrow) represented the predominant population in the reticular connective tissue with similar expression patterns as in the cortical bone (g, h, k, l). No positive staining was found in isotype controls (data not shown). Most of the M1-labeled cells were found attached to bone surfaces instead of M2-labeled cells (m). Representative images from three independent experiments are shown. FOV, field of view. Data shown as the mean±s.d. (*P<0.05). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29263936), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-712_goat-polyclonal-ccr7-antibody-310202415532041.jpg)
![Immunocytochemistry/Immunofluorescence: MHC Class I Antibody (OX18) [NB120-6405] - Major histocompatibility complex (MHC) I and II as well as Transporter associated with antigen presentation II (TAPII) were analyzed, using immunocytochemistry on rat Schwann cells (SCs). Corresponding merges are shown in the bottom rows. Treatment of SCs with IL-17 was performed at concentrations of 0.5 and 50 ng/mL. Graphs to the right show densitometry quantification. SCs showed expression of MHCI > TAPII > MHCII, which increased after IL-17 treatment. MHCI was mainly detected in the cytoplasm and the expression increased in a dose-dependent manner after IL-17 treatment, significant for 0.5 ng/mL and 50 ng/mL (**P TAPII > MHCII, which increased after IL-17 treatment. (A) MHCI was mainly detected in the cytoplasm and the expression increased in a dose-dependent manner after IL-17 treatment, significant for 0.5 ng/mL and 50 ng/mL (**P ≤0.01). (B) MHCII revealed a fainter basic expression emphasizing the nucleus and was found significantly increased after 0.5 ng/mL IL-17 stimulation (**P ≤ 0.01). (C) TAPII was detected in the nucleus and cytoplasm. We detected a dose-dependent tendency but no significantly increased expression after IL-17 stimulation. For MHCI, TAPII and MHCII and the concentrations applied, analysis of variance between the independent experiments revealed no significant difference. DAPI, 4′, 6-diamidino-2-phenylindole. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/24678820), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-85960_rabbit-polyclonal-sfxn2-antibody-western-blot-13220261739815.jpg "Immunocytochemistry/Immunofluorescence: MHC Class I Antibody (OX18) [NB120-6405] - Major histocompatibility complex (MHC) I and II as well as Transporter associated with antigen presentation II (TAPII) were analyzed, using immunocytochemistry on rat Schwann cells (SCs). Corresponding merges are shown in the bottom rows. Treatment of SCs with IL-17 was performed at concentrations of 0.5 and 50 ng/mL. Graphs to the right show densitometry quantification. SCs showed expression of MHCI > TAPII > MHCII, which increased after IL-17 treatment. MHCI was mainly detected in the cytoplasm and the expression increased in a dose-dependent manner after IL-17 treatment, significant for 0.5 ng/mL and 50 ng/mL (**P TAPII > MHCII, which increased after IL-17 treatment. (A) MHCI was mainly detected in the cytoplasm and the expression increased in a dose-dependent manner after IL-17 treatment, significant for 0.5 ng/mL and 50 ng/mL (**P ≤0.01). (B) MHCII revealed a fainter basic expression emphasizing the nucleus and was found significantly increased after 0.5 ng/mL IL-17 stimulation (**P ≤ 0.01). (C) TAPII was detected in the nucleus and cytoplasm. We detected a dose-dependent tendency but no significantly increased expression after IL-17 stimulation. For MHCI, TAPII and MHCII and the concentrations applied, analysis of variance between the independent experiments revealed no significant difference. DAPI, 4′, 6-diamidino-2-phenylindole. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/24678820), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - HMGB1 promoted the activation of canonical NLRP3 inflammasome in retinal IR injury. The intravitreal injection of HMGB1 inhibitor, GA, significantly suppressed mRNA (B) and protein (D) production of NLRP3. Data are shown as mean +/- SD. **P < 0.01 vs sham group. Image collected and cropped by CiteAb from the following publication (//www.jneuroinflammation.com/content/12/1/137) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NLRP3-NALP3-Antibody---BSA-Free-Western-Blot-NBP1-77080-img0011.jpg "Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - HMGB1 promoted the activation of canonical NLRP3 inflammasome in retinal IR injury. The intravitreal injection of HMGB1 inhibitor, GA, significantly suppressed mRNA (B) and protein (D) production of NLRP3. Data are shown as mean +/- SD. **P < 0.01 vs sham group. Image collected and cropped by CiteAb from the following publication (//www.jneuroinflammation.com/content/12/1/137) licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - Staining of NALP3 in K562 cells with NALP3 antibody at 2 ug/mL.](http://images.novusbio.com/fullsize/NLRP3-NALP3-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NBP1-77080-img0010.jpg)
![Immunohistochemistry-Paraffin: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - Analysis of NALP3 in mouse lung tissue using anti-NALP3 antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/NLRP3-NALP3-Antibody---BSA-Free-Immunohistochemistry-Paraffin-NBP1-77080-img0003.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - Analysis of NALP3 in K562 cell lysate with NALP3 antibody at 1 ug/mL (A) in the absence and (B) in the presence of blocking peptide.](http://images.novusbio.com/fullsize/NLRP3-NALP3-Antibody---BSA-Free-Western-Blot-NBP1-77080-img0009.jpg)
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - hADSC-Evs suppressed NLRP3 inflammasome activation in ocular surface of experimental mice under desiccating stress. Representative image of immunofluorescent staining of NLRP3 related genes in corneal and conjunctival epithelia of desiccating mice or treated with hADSC-EVs (*conjunctiva; open triangle cornea). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32884023/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NLRP3-NALP3 Antibody - BSA Free-Immunocytochemistry-Immunofluorescence-NBP1-77080-img0012.jpg)
![Immunocytochemistry/ Immunofluorescence: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - hADSC-Evs suppressed NLRP3 inflammasome activation in ocular surface of experimental mice under desiccating stress. (A) Representative image of immunofluorescent staining of NLRP3 related genes in corneal & conjunctival epithelia of desiccating mice or treated with hADSC-EVs (*conjunctiva; open triangle cornea). (B,C) qRT-PCR showed the mRNA levels of NLRP3 related genes in conjunctiva & cornea (four corneas/conjunctivas were mixed as a sample). Data was shown as mean ± SEM. *p < 0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32884023), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77080_rabbit-polyclonal-nlrp3-nalp3-antibody-31020241535675.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - HMGB1 promoted the activation of canonical NLRP3 inflammasome in retinal IR injury. The intravitreal injection of exogenous rHMGB1 significantly promoted the mRNA & protein production of NLRP3 (a, c) & ASC (e, g) & activation of caspase-1 (i). Thus, the intravitreal injection of HMGB1 inhibitor, GA, significantly suppressed the production of NLRP3 (b, d) & ASC (f, h) & activation of caspase-1 (j). Data are shown as mean ± SD. *P < 0.05, **P < 0.01 vs sham group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26224068), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77080_rabbit-polyclonal-nlrp3-nalp3-antibody-310202415345338.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - Co-immunoprecipitation assay: Figure showing interaction of NLRP3, NLRC4 & NAIP with ASC during CFT073 infection in THP-1m. Cytoplasmic extracts of THP-1m infected with or without CFT073, 6 h post stimulation were subjected to IP & WB by various antibodies (ASC, NLRP3, NLRC4, & NAIP) as described in material & methods. Cytoplasmic extract used as input was subjected to check NLRP3, ASC, NLRC4 & NAIP expression as shown in figure. ASC antibody was used to co-immunoprecipitate the complex from cytoplasmic extracts & then immunoblotted to detect NLRP3, NLRC4 & NAIP. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31551961), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77080_rabbit-polyclonal-nlrp3-nalp3-antibody-310202415371971.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - HMGB1 regulated the activation of NLRP3, rather than the activation of caspase-8, via NF-kappa B pathway. a, b NF-kappa B was activated in ischemic retina at the early stage after reperfusion. c, d Intraocular injection rHMGB1 or GA could promote or suppress the production of phosphor-NF-kappa B p65. e, f Intravitreal injection of NF-kappa B p65 inhibitor, JSH-23, significantly reduced the activation of NLRP3 & decreased the processing of IL-1 beta , g rather than caspase-8. However, intravitreal injection of caspase-8 inhibitor, Z-IETD-fmk, decreased the production of phosphor-NF-kappa B p65, obviously (h). Data are shown as mean ± SD. *P < 0.05, **P < 0.01 vs sham group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26224068), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77080_rabbit-polyclonal-nlrp3-nalp3-antibody-310202415291993.jpg)
![Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - In vitro nephrotoxicity assessment of kidney spheroids. Western blotting analysis of kidney injury markers in kidney spheroids after treatment with 20 uM cisplatin (CPT) or 50 uM cisplatin cyclosporin A (CSA). All data are shown as the means +/- s.e.m. *p < 0.05 compared with control by unpaired Student's t-test. Scale bar, 20 um. Image collected and cropped by CiteAb from the following publication (www.nature.com/articles/s41598-019-53855-2) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Western-Blot-NBP1-76701-img0016.jpg "<b>Biological Strategies Validation. </b>Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - In vitro nephrotoxicity assessment of kidney spheroids. Western blotting analysis of kidney injury markers in kidney spheroids after treatment with 20 uM cisplatin (CPT) or 50 uM cisplatin cyclosporin A (CSA). All data are shown as the means +/- s.e.m. *p < 0.05 compared with control by unpaired Student's t-test. Scale bar, 20 um. Image collected and cropped by CiteAb from the following publication (www.nature.com/articles/s41598-019-53855-2) licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry-Paraffin: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - Analysis of human uterus tissue using anti-TIM-1 antibody (3809) at 10 ug/ml.Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4 C. A goat anti-rabbit IgG H&L (HRP)at 1/250 was used as secondary. Counter stained with Hematoxylin.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Immunohistochemistry-Paraffin-NBP1-76701-img0013.jpg)
![Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - Loading: 15 ug of NIH/3T3 cell lysates. Antibodies: TIM-1 3809 (8 ug/mL), overnight incubation at 4 C in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Western-Blot-NBP1-76701-img0010.jpg)
![<b>Independent Antibodies Validation. </b>Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - Loading: 15 ug of lysates per lane. Antibodies: TIM-1 3809 (8 ug/mL), TIM-13811 (1 ug/mL), beta-actin (1 ug/mL), and GAPDH (0.02 ug/mL), overnightincubation at 4C (3809) or 1h incubation at RT in 5% NFDM/TBST. Secondary:Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Western-Blot-NBP1-76701-img0012.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - HeLa cells were transfected with control siRNAs (lane 1) or TIM-1 siRNAs (lane 2) Loading: 15 ug of HeLa whole cell lysates per lane. Antibodies: 3809 (8 ug/mL), 1 hincubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Western-Blot-NBP1-76701-img0015.jpg)
![Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - Figure 1 Western Blot Validation in Human Cell LinesLoading: 15 u of lysates per lane.Antibodies: TIM-1 (8 u/mL), overnight incubation at 4; C in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/nbp1-76701_rabbit-polyclonal-tim-1-kim-1-havcr-antibody-2711202420171718.gif)
![Immunocytochemistry/ Immunofluorescence: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - Validation of TIM-1/KIM-1/HAVCR in Human Uterus Cells. Immunofluorescent analysis of 4% paraformaldehyde-fixed human uterus cells labeling TIM-1/KIM-1/HAVCR with at 20 ug/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red). Image showing both membrane and cytoplasmic staining on human uterus cells.](http://images.novusbio.com/fullsize/nbp1-76701_rabbit-polyclonal-tim-1-kim-1-havcr-antibody-271120241937768.jpg)
![Immunohistochemistry-Frozen: HLA ABC Antibody (W6/32) [NB100-64775] - Analysis of Mouse colon cancer tissue using HLA ABC antibody (W6/32). Primary antibody dilution was 1:100. Sample was incubated with secondary antibody in 1:300 dilution. Image from verified customer review.](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Immunohistochemistry-Frozen-NB100-64775-img0015.jpg "Immunohistochemistry-Frozen: HLA ABC Antibody (W6/32) [NB100-64775] - Analysis of Mouse colon cancer tissue using HLA ABC antibody (W6/32). Primary antibody dilution was 1:100. Sample was incubated with secondary antibody in 1:300 dilution. Image from verified customer review.")
![Flow Cytometry: HLA ABC Antibody (W6/32) [NB100-64775] - Analysis using the FITC conjugate of NB100-64775. Staining of normal human peripheral blood cells with Mouse IgG2a K Isotype Control FITC (NBP1-43955) (blue histogram) or Anti-Human HLA-ABC FITC (purple histogram). Cells in the lymphocyte gate were used f](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Flow-Cytometry-NB100-64775-img0013.jpg)
![Flow Cytometry: HLA ABC Antibody (W6/32) [NB100-64775] - Staining of human peripheral blood lymphocytes with Mouse anti Human HLA ABC.](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Flow-Cytometry-NB100-64775-img0002.jpg)
![Flow Cytometry: HLA ABC Antibody (W6/32) [NB100-64775] - Staining of human peripheral blood lymphocytes with Mouse anti Human HLA ABC:Alexa Fluor 488.](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Flow-Cytometry-NB100-64775-img0004.jpg)
![Flow Cytometry: HLA ABC Antibody (W6/32) [NB100-64775] - Staining of human peripheral blood lymphocytes with Mouse anti Human HLA ABC:Alexa Fluor 647.](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Flow-Cytometry-NB100-64775-img0006.jpg)
![Flow Cytometry: HLA ABC Antibody (W6/32) [NB100-64775] - Staining of human peripheral blood lymphocytes with Mouse anti Human HLA ABC:FITC.](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Flow-Cytometry-NB100-64775-img0007.jpg)
![Flow Cytometry: HLA ABC Antibody (W6/32) [NB100-64775] - Staining of human peripheral blood monocytes with Mouse anti Human HLA ABC:Biotin.](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Flow-Cytometry-NB100-64775-img0008.jpg)
![Flow Cytometry: HLA ABC Antibody (W6/32) [NB100-64775] - Human lymphoblast. Image provided via verified customer review.](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Flow-Cytometry-NB100-64775-img0009.jpg)
![Flow Cytometry: HLA ABC Antibody (W6/32) [NB100-64775] - Staining of peripheral blood lymphocytes with anti-HLA-ABC: Low Endotoxin.](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Flow-Cytometry-NB100-64775-img0010.jpg)
![Flow Cytometry: HLA ABC Antibody (W6/32) [NB100-64775] - Analysis using the PE/Cy5 conjugate of NB100-64775. Staining of normal human peripheral blood cells with Mouse IgG2a K Isotype Control PE-Cy5 (NBP1-43073) (blue histogram) or Anti-Human HLA-ABC PE-Cy5 (purple histogram). Cells in the lymphocyte gate were](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Flow-Cytometry-NB100-64775-img0014.jpg)
![Western Blot: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Western blot shows lysates of Ramos human Burkitt's lymphoma parental cell line and B7-2 knockout (KO) Ramos cell line. PVDF membrane was probed with 1.0 ug/mL of Mouse Anti-Human B7-2 Monoclonal Antibody (Catalog # NBP2-25208) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog #HAF018). Specific band was detected for B7-2 at approximately 90 kDa (as indicated) in the parental Ramos cell line, but is not detectable in the knockout Ramos cell line. This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/B7-2-CD86-Antibody-BU63-Knockout-Validated-NBP2-25208-img0005.jpg "<b>Genetic Strategies Validation. </b>Western Blot: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Western blot shows lysates of Ramos human Burkitt's lymphoma parental cell line and B7-2 knockout (KO) Ramos cell line. PVDF membrane was probed with 1.0 ug/mL of Mouse Anti-Human B7-2 Monoclonal Antibody (Catalog # NBP2-25208) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog #HAF018). Specific band was detected for B7-2 at approximately 90 kDa (as indicated) in the parental Ramos cell line, but is not detectable in the knockout Ramos cell line. This experiment was conducted under reducing conditions.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Macrophage polarization states. Distribution and proportion of CD86+ macrophages (brown) were identified using IHC procedures. Intensity for the color response to antibodies was visible in lung tissues from all groups. Population proportions for the stained cells as shown by red arrows were calculated as a fold change of the control. (d). The results were expressed as Mean +/- SD (n = 3). **: a p-value of < 0.01 vs NS, OVA/BUD and OVA/PCI except the number of CD86+ cells in OVA/PCI group. #: P < 0.05 vs NS and ##; P < 0.01 vs either NS or OVA/BUD group. Image collected and cropped by CiteAb from the following publication (//respiratory-research.biomedcentral.com/articles/10.1186/s12931-020-1322-5) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/B7-2-CD86-Antibody-BU63-Immunohistochemistry-NBP2-25208-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Immunofluorescence staining of PFA-fixed Ramos cells using followed by goat anti-Mouse IgG conjugated to CF488 (green). Nuclei are stained with Red Dot.](http://images.novusbio.com/fullsize/B7-2-CD86-Antibody-BU63-Immunocytochemistry-Immunofluorescence-NBP2-25208-img0006.jpg)
![Immunohistochemistry: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Effects of 20(S)-Rg3 on macrophage polarization in atherosclerotic lesions of diabetic ApoE-/- mice. Co-immunofluorescence staining for macrophage (anti-Moma-2 antibody, green), M1 marker CD86 (red) and DAPI (blue) (n = 5, respectively). Scale bar: 20 um. Image collected and cropped by CiteAb from the following publication (//www.frontiersin.org/articles/10.3389/fphar.2018.00464/full) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/B7-2-CD86-Antibody-BU63-Immunohistochemistry-NBP2-25208-img0010.jpg)
![Flow Cytometry: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Flow Cytometric Analysis of PFA-fixed Ramos cells. B7-2/CD86 Antibody (BU63) followed by goat anti-Mouse IgG-CF488 (Blue); Isotype Control (Red).](http://images.novusbio.com/fullsize/B7-2-CD86-Antibody-BU63-Flow-Cytometry-NBP2-25208-img0008.jpg)
![Immunohistochemistry-Paraffin: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Formalin-fixed, paraffin-embedded esophagus tumor tissue stained with CD86 antibody (5 ug/ml), peroxidase-conjugate and DAB chromogen. Note strong staining of differentiated squamous cells. TMA was used for this test.](http://images.novusbio.com/fullsize/B7-2-CD86-Antibody-BU63-Immunohistochemistry-Paraffin-NBP2-25208-img0004.jpg)
![Flow Cytometry: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Flow Cytometric Analysis of human PBMCs using B7-2/CD86 Antibody (BU63); Goat anti-Mouse IgG-CF488 (red); Isotype Control (green).](http://images.novusbio.com/fullsize/B7-2-CD86-Antibody-BU63-Flow-Cytometry-NBP2-25208-img0007.jpg)
![Immunohistochemistry: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Macrophage polarization states. Distribution & proportion of CD68+ (a), CD86+ (c) & CD163+ (e) macrophages (brown) were identified using IHC procedures. Intensity for the color response to antibodies was visible in lung tissues from all groups. Population proportions for the stained cells as shown by red arrows were calculated as a fold change of the control. (b, d, f). The results were expressed as Mean ± SD (n = 3). **: a p-value of < 0.01 vs NS, OVA/BUD & OVA/PCI except the number of CD86+ cells in OVA/PCI group. #: P < 0.05 vs NS & ##; P < 0.01 vs either NS or OVA/BUD group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32111211), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-25208_mouse-monoclonal-b7-2-cd86-antibody-bu63-imgenex-img-6882a-25ug-31020241534324.jpg)
![Immunocytochemistry/ Immunofluorescence: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Effects of 20(S)-Rg3 on macrophage polarization in atherosclerotic lesions of diabetic ApoE–/– mice. (A,B) Co-immunofluorescence staining of the aortic root for macrophage (anti-Moma-2 antibody, green) & M1 marker iNos (red), & a bar graph summarizing the results (n = 5, respectively). (C,D) Co-immunofluorescence staining for macrophage (anti-Moma-2 antibody, green) & M1 marker CD86 (red), & a bar graph summarizing the results (n = 5, respectively). Scale bar: 20 μm. Data are mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29867472), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-25208_mouse-monoclonal-b7-2-cd86-antibody-bu63-imgenex-img-6882a-25ug-31020241535650.jpg)
![M1 macrophages were induced in the in vivo mouse intervertebral disc (mIVD) degeneration model (puncture model). (a) Immunohistological analysis of Iba-1, iNOS, and arginase (brown staining) expression in nucleus pulposus (NP), annulus fibrosis (AF), and cartilage endplate (CEP) [right] at high magnification and in whole mIVDs (left) at low magnification. Images using an IgG isotype control antibody are included to demonstrate the specificity of the IHC staining. (b) Protein was extracted from punctured mIVDs in the puncture model, and western blotting was performed using antibodies against CD86, CD163, and beta -actin. (c) Images of the panel in (b), captured using a ChemiDoc Touch system and quantified using ImageJ. Biological and technical replicates were performed three times. Values represent the mean +/- SD. *p < 0.05, **p < 0.01, relative to the corresponding control. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/41053148), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-25208_mouse-monoclonal-b7-2-cd86-antibody-bu63-western-blot-13220261327102.jpg)
![Western Blot: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis using MCP1 mouse mAb against A549 (1), HeLa (2), Raw264.7 (3), L1210 (4), C6 (5), and COS-7 (6) cell lysates.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Western-Blot-NBP2-22115-img0003.jpg "Western Blot: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis using MCP1 mouse mAb against A549 (1), HeLa (2), Raw264.7 (3), L1210 (4), C6 (5), and COS-7 (6) cell lysates.")
![Immunocytochemistry/Immunofluorescence: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis of HepG2 cells using A) MCP1 mAb (green), DRAQ5 fluorescent DNA dye (blue), and Actin filaments have been labeled with Alexa Fluor-555 phalloidin (red). B) Staining without MCP1 mAb](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Immunocytochemistry-Immunofluorescence-NBP2-22115-img0011.jpg)
![Immunohistochemistry: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - HER2 activates NF-kB and upregulates CCL2. MGs from FVB wild-type and 22-week-old MMTV-HER2 mice stained against CCL2, HER2, and CCR2. Bars: 25 um. Inset, CCR2 signal, zoom factor 1x; full image in Supplementary Fig. 5i. CCL2 intensity was quantified using ROI tool in Metamorph (Supplementary Fig. 5h). Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-017-02481-5), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Immunohistochemistry-NBP2-22115-img0009.jpg)
![Flow Cytometry: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis of A549 cells using MCP1 mouse mAb (green) and negative control (red).](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Flow-Cytometry-NBP2-22115-img0004.jpg)
![Western Blot: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis using MCP1 mAb against human MCP1 (AA: 1-99) recombinant protein. (Expected MW is 36.5 kDa)](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Western-Blot-NBP2-22115-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - CCL2 staining in acini cultures from MMTV-HER2 MGs (20-24 weeks) grown for 5 days and then DMSO-treated (vehicle control, e), 1uM lapatinib (f) or 1 uM IKKi compound A (g) for 24 hrs. Bar: 25 um. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-017-02481-5), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Immunocytochemistry-Immunofluorescence-NBP2-22115-img0010.jpg)
![<b>Biological Strategies Validation. </b>Immunohistochemistry: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Organotypic specimens were treated with anti-LIF for 72 h and then cultured with PBMCs for 24 h. CXCL9 and CCL2 mRNA expression levels are shown. Representative images (patient 4, 5, 6) of CFSE-stained PBMCs into Matrigel containing GBM specimens and IF of the indicated factors in organotypic tissues are displayed. Bars represent quantification of five different fields of each condition. Data are presented as mean +/- SD. Scale bar, 20 um. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31186412/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Immunohistochemistry-NBP2-22115-img0012.jpg)
![Immunohistochemistry-Paraffin: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis of paraffin-embedded liver cancer tissues using MCP1 mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Immunohistochemistry-Paraffin-NBP2-22115-img0007.jpg)
![ELISA: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Red: Control Antigen (100ng), Purple: Antigen (10ng), Green: Antigen (50ng), Blue: Antigen (100ng).](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-ELISA-NBP2-22115-img0001.jpg)
![Immunocytochemistry/ Immunofluorescence: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Expression patterns of CCL2 & CCR2 in unwounded & wounded corneas of WT & MMP12 KO mice. (A) Immunofluorescence of CCL2 chemokine & (B) its receptor CCR2 in unwounded & chemically wounded (2-days after injury) WT & Mmp12−/− mouse corneas. Control images represent mouse corneas stained with secondary antibody only & without primary antibody. Nuclei were visualized by staining with DAPI (blue). Scale bars: 50 µm. A magnified image of a wounded WT cornea shows perinuclear expression of CCL2 (orange box). CCL2 staining was visualized in epithelial, stromal, & endothelial layers of wounded WT & Mmp12−/− corneas. CCR2 staining was visualized in epithelial & stromal layers of unwounded & wounded WT & Mmp12−/− corneas. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31399604), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-22115_mouse-monoclonal-ccl2-mcp1-antibody-2d8-310202415384136.jpg)
![Immunocytochemistry/ Immunofluorescence: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - LIF represses CXCL9 through epigenetic silencing. a, b qRT-PCR analysis of the indicated genes in BMDMs. BMDMs were pre-incubated with 20 ng/ml LIF for 72 h & then stimulated with 5 ng/ml IFN gamma or 10 μg/ml IL4 during 6 h (a) or with 0.1, 0.5, 1 & 5 ng/ml IFN gamma for 24 h (b). c CXCL9 ELISA from BMDMs pre-incubated with 20 ng/ml LIF & then stimulated with 0.1 ng/ml IFN gamma for 24 h. d CXCL9 ELISA from human CD11b+sorted cells (77% CD11b+ CD14+, see Supplementary Fig. 7b, c) from human GBM cultured with 20 ng/ml LIF for 72 h & then with 0.1 ng/ml IFN gamma for 24 h. e ChIP of Tri-methyl-histone H3 (H3K27me3), EZH2 & acetyl-histone4 (H4ac) was performed in BMDMs treated with 20 ng/ml LIF for 72 h. Scheme shows the analysed CXCL9 promoter region. Representative data are presented as mean ± SD. f Representative images of IF of the indicated markers in human GBM organotypic slices (patients 1, 2, 3) incubated with 10 μg/ml anti-LIF for 3 days. Scale bar, 20 μm. (see Supplementary Fig. 8). Bottom, percentage of double positive cells relative to Iba1+ cells & percentage of CXCL9+ cells relative to the total number of cells. Data are mean of all patients ± SEM. Statistical analyses by Student’s t-test or Mann–Whitney T-test. *P < 0.05, **P < 0.01; ***P < 0.001; ****P < 0.0001 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31186412), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-22115_mouse-monoclonal-ccl2-mcp1-antibody-2d8-3102024161360.jpg)
![Immunohistochemistry: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - LIF regulates CXCL9, CCL2, CD206, & CD163 in TAMs. a Differential expression analysis of isolated CD11b+ cells from anti-LIF treated ID8 mice vs. control. Volcano plot representing the genes significantly (Q-value < 0.1) overexpressed (brown) & significantly underexpressed (turquoise). Heatmap representing the expression values of the indicated genes, each column represents a sample & each row a gene. The last column represents the log2 fold change (log2 FC) of gene expression. b mRNA expression for the indicated genes in isolated CD11b+ cells from anti-LIF treated or untreated ID8 & GL261N tumors. c Percentage & mean fluorescence intensity (MFI) of CCL2 & CXCL9 in TAMs (CD11b+ Ly6G− Ly6C−) from anti-LIF treated or untreated GL261N tumors. d Representative IF images of Iba1 & the indicated markers stainings of GL261N tumors (see Supplementary Fig. 4). Scale bar, 20 μm. Bottom, percentage of double positive cells relative to the TAM marker positive cells. CXCL9 quantification is relative to the total number of cells. e Tumor growth of GL261N in WT, CXCL9−/−, & CCL2−/− mice or mice treated with the indicated antibodies is shown as total flux (p/s). f Fold change (FC) of tumor infiltrating CD8+ T cells in the indicated treatments. Data are mean ± SEM. g, h Representative IHC of the indicated markers from 20 GBM tumors. The degree of staining was quantified using H-score method. Correlations between LIF & CCL2, CD206, CD163, & CXCL9 with the R-squared coefficients (R2) were calculated (h). Statistical analyses by Mann–Whitney T-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31186412), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-22115_mouse-monoclonal-ccl2-mcp1-antibody-2d8-310202416114760.jpg)
![Immunocytochemistry/ Immunofluorescence: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - LIF regulates CXCL9, CCL2, CD206, & CD163 in TAMs. a Differential expression analysis of isolated CD11b+ cells from anti-LIF treated ID8 mice vs. control. Volcano plot representing the genes significantly (Q-value < 0.1) overexpressed (brown) & significantly underexpressed (turquoise). Heatmap representing the expression values of the indicated genes, each column represents a sample & each row a gene. The last column represents the log2 fold change (log2 FC) of gene expression. b mRNA expression for the indicated genes in isolated CD11b+ cells from anti-LIF treated or untreated ID8 & GL261N tumors. c Percentage & mean fluorescence intensity (MFI) of CCL2 & CXCL9 in TAMs (CD11b+ Ly6G− Ly6C−) from anti-LIF treated or untreated GL261N tumors. d Representative IF images of Iba1 & the indicated markers stainings of GL261N tumors (see Supplementary Fig. 4). Scale bar, 20 μm. Bottom, percentage of double positive cells relative to the TAM marker positive cells. CXCL9 quantification is relative to the total number of cells. e Tumor growth of GL261N in WT, CXCL9−/−, & CCL2−/− mice or mice treated with the indicated antibodies is shown as total flux (p/s). f Fold change (FC) of tumor infiltrating CD8+ T cells in the indicated treatments. Data are mean ± SEM. g, h Representative IHC of the indicated markers from 20 GBM tumors. The degree of staining was quantified using H-score method. Correlations between LIF & CCL2, CD206, CD163, & CXCL9 with the R-squared coefficients (R2) were calculated (h). Statistical analyses by Mann–Whitney T-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31186412), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-22115_mouse-monoclonal-ccl2-mcp1-antibody-2d8-31020241613617.jpg)
![Western Blot: CD81 Antibody (1D6) [NB100-65805] - Isolation and characterization of exosomes from cell culture supernatant and human blood. Immunoblot of exosomal markers CD81 (~30 kDa), CD63 (~55 kDa), and LAMP2B (~50 kDa) in exosomes (5 ug lysates) isolated from the serum of breast cancer patients and healthy control. Grp94 (~100 kDa) and beta-actin (~42 kDa) serve as a negative control and a loading control, respectively. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep36502), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD81-Antibody-1D6-Western-Blot-NB100-65805-img0015.jpg "Western Blot: CD81 Antibody (1D6) [NB100-65805] - Isolation and characterization of exosomes from cell culture supernatant and human blood. Immunoblot of exosomal markers CD81 (~30 kDa), CD63 (~55 kDa), and LAMP2B (~50 kDa) in exosomes (5 ug lysates) isolated from the serum of breast cancer patients and healthy control. Grp94 (~100 kDa) and beta-actin (~42 kDa) serve as a negative control and a loading control, respectively. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep36502), licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: CD81 Antibody (1D6) [NB100-65805] - Staining of TAPA1 in human testis using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/CD81-Antibody-1D6-Immunohistochemistry-Paraffin-NB100-65805-img0003.jpg)
![Flow Cytometry: CD81 Antibody (1D6) - BSA Free [NB100-65805] - A surface stain was performed on Jurkat cells with CD81 Antibody (1D6) NB100-65805 (blue) and a matched isotype control MAB002 (orange). Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (84540, Thermo Fisher).](http://images.novusbio.com/fullsize/CD81-Antibody-1D6-BSA-Free-Flow-Cytometry-NB100-65805-img0016.jpg)
![Western Blot: CD81 Antibody (1D6) [NB100-65805] - Analysis of human testis tissue (A) using CD81 antibody at a concentration of 2 ug/mL.](http://images.novusbio.com/fullsize/CD81-Antibody-1D6-Western-Blot-NB100-65805-img0007.jpg)
![Flow Cytometry: CD81 Antibody (1D6) [NB100-65805] - Surface flow cytometric staining of 1 x 10^6 PBMC cells using CD81 antibody (dark blue). Isotype control shown in orange. An antibody concentration of 1 ug/1 x 10^6 cells was used.](http://images.novusbio.com/fullsize/CD81-Antibody-1D6-Flow-Cytometry-NB100-65805-img0009.jpg)
![Flow Cytometry: CD81 Antibody (1D6) [NB100-65805] - Staining of human peripheral blood lymphocytes.](http://images.novusbio.com/fullsize/CD81-Antibody-1D6-Flow-Cytometry-NB100-65805-img0001.jpg)
![Flow Cytometry: CD81 Antibody (1D6) [NB100-65805] - Analysis using the FITC conjugate of NB100-65805. Staining of human peripheral blood lymphocytes.](http://images.novusbio.com/fullsize/CD81-Antibody-1D6-Flow-Cytometry-NB100-65805-img0011.jpg)
![Flow Cytometry: CD81 Antibody (1D6) [NB100-65805] - A surface stain was performed on Jurkat cells with CD81 (1D6) antibody NB100-65805AF647(blue) and a matched isotype control NBP2-27287AF647 (orange). Cells were incubated in an antibody dilution of 2 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/CD81-Antibody-1D6-Flow-Cytometry-NB100-65805-img0012.jpg)
![Flow Cytometry: CD81 Antibody (1D6) [NB100-65805] - A surface stain was performed on Jurkat Cells with CD81 Antibody (1D6) NB100-65805B and a matched isotype control. Both antibodies were conjugated to biotin. Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature, followed by Streptavidin - R-Phycoerythrin Protein (2012-1000, Novus Biologicals).](http://images.novusbio.com/fullsize/CD81-Antibody-1D6-Flow-Cytometry-NB100-65805-img0013.jpg)
![Flow Cytometry: CD81 Antibody (1D6) [NB100-65805] - A surface stain was performed on Jurkat cells with CD81 Antibody [1D6] NB100-65805AF488 (blue) and a matched isotype control (orange). Cells were incubated in an antibody dilution of 5 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/CD81-Antibody-1D6-Flow-Cytometry-NB100-65805-img0014.jpg)
![Western Blot: CD81 Antibody (1D6) - BSA Free [NB100-65805] - Characterization & internalization of M2-Exos. (A) TEM image of M2-Exos. Scale bar: 200 nm. (B) DLS measurement of M2-Exos size. (C) Western blotting assay of exosomal markers in THP-1-M2 cellular lysate & M2-Exos preparation. (D,F) Fluorescence images of 786-O & ACHN cells treated with or without PKH67-labeled M2-Exos (green). Scale bar: 50 μm. (E,G) Three-dimensional confocal reconstruction of 786-O & ACHN cells treated with PKH67-labeled M2-Exos (green). (H) Fluorescence staining analyzing the internalization of M2-Exos by 786-O cells over 12 h. Scale bar: 10 μm. CT: control. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35328425), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-65805_mouse-monoclonal-cd81-antibody-1d6-310202415382443.jpg)
![Western Blot: TLR5 Antibody (85B152.5) [NBP1-97728] - Normal human bronchial epithelial total cell lysate. Image from verified customer review.](http://images.novusbio.com/fullsize/TLR5-Antibody-85B152-5-Western-Blot-NBP1-97728-img0003.jpg "Western Blot: TLR5 Antibody (85B152.5) [NBP1-97728] - Normal human bronchial epithelial total cell lysate. Image from verified customer review.")
![Flow Cytometry: TLR5 Antibody (85B152.5) [NBP1-97728] - Analysis using the FITC conjugate of NBP1-97728. Staining of TLR5 in 10^6 cells using 0.5 ugs of FITC-conjugated antibody: A) Intracellular flow testing of human Ramos cells and B) cell surface flow testing of mouse RAW cells. The shaded (or black) histogram represents cells without antibody, green represents isotype control antibody, and red represents TLR5 antibody.](http://images.novusbio.com/fullsize/TLR5-Antibody-85B152-5-Flow-Cytometry-NBP1-97728-img0009.jpg)
![Flow Cytometry: TLR5 Antibody (85B152.5) [NBP1-97728] - Intracellular flow analysis of TLR5 in Ramos cells using 1 ug of TLR5 antibody. Shaded histogram represents Ramos cells without antibody; green represents isotype control antibody; red represents TLR5 antibody.](http://images.novusbio.com/fullsize/TLR5-Antibody-85B152-5-Flow-Cytometry-NBP1-97728-img0002.jpg)
![Flow Cytometry: TLR5 Antibody (85B152.5) [NBP1-97728] - Intracellular flow analysis of TLR5 in 10^6 human lymphocytes using 0.5 ug of NB200-571. The shaded histogram represents cells without antibody, green represents isotype control (BD), and red represents TLR5 antibody.](http://images.novusbio.com/fullsize/TLR5-Antibody-85B152-5-Flow-Cytometry-NBP1-97728-img0006.jpg)
![Flow Cytometry: TLR5 Antibody (85B152.5) [NBP1-97728] - Analysis using the PE conjugate of NBP1-97728. Staining of TLR5 in 10^6 RAW cells using 0.5 ugs of PE-conjugated antibody. The black histogram represents cells without antibody, green represents isotype control antibody, and red represents TLR5 antibody.](http://images.novusbio.com/fullsize/TLR5-Antibody-85B152-5-Flow-Cytometry-NBP1-97728-img0007.jpg)
![Flow Cytometry: TLR5 Antibody (85B152.5) [NBP1-97728] - Analysis using the PE conjugate of NBP1-97728. Staining of TLR5 in 10^6 human lymphocytes using 0.5 ugs of PE-conjugated antibody. The shaded histogram represents cells without antibody, green represents isotype control antibody, and red represents TLR5 antibody.](http://images.novusbio.com/fullsize/TLR5-Antibody-85B152-5-Flow-Cytometry-NBP1-97728-img0008.jpg)
![Flow Cytometry: TLR5 Antibody (85B152.5) [NBP1-97728] - TLR expression in USSCs. Flow cytometry detection of TLRs in USSCs using TLR5 antibody. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/20196781/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/nbp1-97728_mouse-monoclonal-tlr5-antibody-85b152-5-25520231539519.jpg)
![Western Blot: TNF-alpha Antibody - Azide Free [NB600-587] - Analysis using Azide/BSA FREE version of NB600-587. Membrane blocked in 1% BSA-TBS-T 30 min RT, 1:1000 dilution in 1% BSA-TBS-T 4C.](http://images.novusbio.com/fullsize/TNF-alpha-Antibody---Azide-Free-Western-Blot-NB600-587-img0012.jpg "Western Blot: TNF-alpha Antibody - Azide Free [NB600-587] - Analysis using Azide/BSA FREE version of NB600-587. Membrane blocked in 1% BSA-TBS-T 30 min RT, 1:1000 dilution in 1% BSA-TBS-T 4C.")
![Western Blot: TNF-alpha Antibody - Azide Free [NB600-587] - Expression of TNF-alpha, IL-1beta and NF-kappaB in the brains of MCAO rats. Western blot confirmed that protein levels of TNF-alpha increased as early as 4 h after reperfusion, further increased at 24 h, peaked at 72 h and decreased at 7 days, respectively (*P<0.001, compared with the controls; #P<0.001 compared with the previous time point). Five rats in each group were used for western blot (n=5), sham, sham-operated control rats Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/cddis2014586), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TNF-alpha-Antibody---Azide-Free-Western-Blot-NB600-587-img0014.jpg)
![Immunocytochemistry/Immunofluorescence: TNF-alpha Antibody - Azide Free [NB600-587] - LMP2 knockdown by shRNA reduced the expression of TNF-alpha and IL-1beta after MCAO. Immunofluorescence labeling revealed that both TNF-alpha and IL-1beta immunoreactivity was significantly upregulated in the ipsilateral ischemic hemisphere compared with sham-operated animals. In contrast, LMP2 knockdown by shRNA significantly reduced the expression of TNF-alpha and IL-1beta. Five rats in each group were used for immunofluorescent assays (n=5). Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/cddis2014586), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TNF-alpha-Antibody---Azide-Free-Immunocytochemistry-Immunofluorescence-NB600-587-img0015.jpg)
![Immunohistochemistry: TNF-alpha Antibody - Azide Free [NB600-587] - Staining of formalin/PFA-fixed paraffin-embedded sections of human artery tissue sections. Sections were fixed in formaldehyde and subjected to heat mediated antigen retrieval in citrate buffer (pH 6.0). Slides were blocked for ten minutes with 1.5% serum. Primary antibody was diluted 1:100 and incubated with samples for 24 hours at 4C. HRP-conjugated goat anti-rabbit antibody was used as the secondary antibody.](http://images.novusbio.com/fullsize/TNF-alpha-Antibody---Azide-Free-Immunohistochemistry-NB600-587-img0008.jpg)
![Western Blot: TNF-alpha Antibody - Azide Free [NB600-587] - Expression of TNF-alpha, IL-1beta and NF-kappaB in the brains of MCAO rats. Western blot confirmed that protein levels of TNF-alpha increased as early as 4 h after reperfusion, further increased at 24 h, peaked at 72 h and decreased at 7 days, respectively (*P<0.001, compared with the controls; #P<0.001 compared with the previous time point). Five rats in each group were used for western blot (n=5), sham, sham-operated control rats Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/cddis2014586), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TNF-alpha-Antibody---Azide-Free-Western-Blot-NB600-587-img0013.jpg)
![Western Blot: CCL2/MCP1 Antibody [NBP1-07035] - Western blot for MCP-1 protein was analyzed from the ox-LDL-stimulated THP-1 cells. B-actin was used as loading control (D-I). Scale bar: 20 um. Bar graph indicates the mean +/- SD (n = 3). *P < 0.05 and **P < 0.01 vs. Cont group (0 ug/mL of ox-LDL). Image collected and cropped by Citeab from the following publication (SIRT1 inhibition promotes atherosclerosis through impaired autophagy. Oncotarget (2017)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-Western-Blot-NBP1-07035-img0014.jpg "<b>Biological Strategies Validation. </b>Western Blot: CCL2/MCP1 Antibody [NBP1-07035] - Western blot for MCP-1 protein was analyzed from the ox-LDL-stimulated THP-1 cells. B-actin was used as loading control (D-I). Scale bar: 20 um. Bar graph indicates the mean +/- SD (n = 3). *P < 0.05 and **P < 0.01 vs. Cont group (0 ug/mL of ox-LDL). Image collected and cropped by Citeab from the following publication (SIRT1 inhibition promotes atherosclerosis through impaired autophagy. Oncotarget (2017)) licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry-Paraffin: CCL2/MCP1 Antibody [NBP1-07035] - IHC analysis of a formalin-fixed paraffin-embedded (FFPE) human breast carcinoma tissue section using 1:1000 dilution of CCL2/MCP1 antibody (NBP1-07035) on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) with 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching using peroxide block. The sections were incubated with primary antibody for 30 minutes. Bond Polymer Refine Detection (Leica Biosystems) and DAB were used for signal detection which followed counterstaining with hematoxylin. Whole slide scanning and capturing of representative images (20X) were performed using Aperio AT2 (Leica Biosystems). This antibody generated a diffused cytoplasmic staining of CCL2 antigen in the cancer cells, stromal cells as well as the endothelial cells. The stroma itself showed a weak immunopositivity for CCL2. Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-Immunohistochemistry-Paraffin-NBP1-07035-img0007.jpg)
![Western Blot: CCL2/MCP1 Antibody [NBP1-07035] - Inhibition of SIRT1 using EX-527 or SIRT1 siRNA transfection enhanced MCP-1 expression and foam cell formationHuman THP-1 macrophages were pretreated with EX-527 (2 uM, for 2 hrs) or SIRT1 siRNA (20 uM, for 24 hrs), and then exposed to 80 i1/4g/mL of ox-LDL for an additional 24 hrs. Western blot for SIRT1 and MCP-1 proteins were analyzed from the ox-LDL-stimulated THP-1 cells. I2-actin was used as loading control. Image collected and cropped by Citeab from the following publication (SIRT1 inhibition promotes atherosclerosis through impaired autophagy. Oncotarget (2017)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-Western-Blot-NBP1-07035-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: CCL2/MCP1 Antibody [NBP1-07035] - MCP1 antibody was tested in HeLa cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-07035-img0006.jpg)
![Immunohistochemistry-Paraffin: CCL2/MCP1 Antibody [NBP1-07035] - IHC analysis of a formalin-fixed paraffin-embedded (FFPE) human breast carcinoma tissue section using 1:1000 dilution of CCL2/MCP1 antibody (NBP1-07035) on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) with 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching using peroxide block. The sections were incubated with primary antibody for 30 minutes. Bond Polymer Refine Detection (Leica Biosystems) and DAB were used for signal detection which followed counterstaining with hematoxylin. Whole slide scanning and capturing of representative images (20X) were performed using Aperio AT2 (Leica Biosystems). This antibody generated a diffused cytoplasmic staining of CCL2 antigen in the cancer cells, stromal cells as well as the endothelial cells. The stroma itself showed a weak immunopositivity for CCL2. Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-Immunohistochemistry-Paraffin-NBP1-07035-img0008.jpg)
![Western Blot: CCL2/MCP1 Antibody [NBP1-07035] - CCL2 expression level was evaluated in control group and aLAG-3 group.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-Western-Blot-NBP1-07035-img0009.jpg)
![Western Blot: CCL2/MCP1 Antibody - BSA Free [NBP1-07035] - Ox-LDL induced macrophage foam cell formation, SIRT1 inhibition, autophagy impairment, & MCP-1 production in THP-1 cellsHuman THP-1 macrophages were exposed to 0, 20, 40, 60, & 80 μg/mL of ox-LDL for 24 hrs. Treated cells were photographed using light microscopy (A). The THP-1 macrophage-derived foam cell formation was determined using ORO staining method (B) & (C). Western blot for SIRT1, LC3, Beclin1, p62, & MCP-1 proteins were analyzed from the ox-LDL-stimulated THP-1 cells. beta -actin was used as loading control (D-I). Scale bar: 20 μm. Bar graph indicates the mean ± SD (n = 3). *P < 0.05 & **P < 0.01 vs. Cont group (0 μg/mL of ox-LDL). Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.17691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-07035_rabbit-polyclonal-ccl2-mcp1-antibody-310202415304238.jpg)
![Western Blot: CCL2/MCP1 Antibody - BSA Free [NBP1-07035] - Inhibition of autophagy with 3-MA led to increased foam cell formation & MCP-1 productionHuman THP-1 macrophages were pretreated with 3-MA (5 μM) for 2 hrs, & then exposed to 80 μg/mL of ox-LDL for an additional 24 hrs. Western blot for LC3, Beclin1, p62, & MCP-1 proteins were analyzed from the ox-LDL-stimulated THP-1 cells. beta -actin was used as loading control (A-E). THP-1 macrophage-derived foam cell formation was determined using ORO staining method (F-G). Scale bar: 40 μm. Bar graph indicates the mean ± SD (n = 3). *P < 0.05 & **P < 0.01 vs. Cont group; #P < 0.05 & ##P < 0.01 vs. 3-MA group; &P < 0.05 & &&P < 0.01 represent significant differences between ox-LDL group & 3-MA+ox-LDL group. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.17691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-07035_rabbit-polyclonal-ccl2-mcp1-antibody-310202415384154.jpg)
![Immunocytochemistry/ Immunofluorescence: CCL2/MCP1 Antibody - BSA Free [NBP1-07035] - CCL2-ir cellular distribution in ependymal layers attached to the CC. A, B CCL2-ir (CCL2 panels, arrows) & GFAP (GFAP panels, arrowheads) double immunostained structures (Merged panels, arrow-arrowheads) are seen inlaid in the ependymal layers attached to the CC in both saline & LPS injected mice. C A CCL2-ir & Iba-1 double labeled soma (Merged, arrow-arrowhead) is seen at a corner of lateral ventricle, which seems be just next to an invaginated choroid plexus between the CC & basal ganglion (framed areas & insets). D, E Hyper-ramified & amoeba like Iba-1 labeled cells (Iba-1 panel, opened arrowheads) are observed in the CC of LPS injected mice, indicating their activated states. The CCL2-ir & Iba-1 double labeled structures are also regarded in the ependymal layers (Merged, arrow-arrowheads). Scare bar = 100 µm in all A– E Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35354428), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-07035_rabbit-polyclonal-ccl2-mcp1-antibody-310202416161849.jpg)
![Western Blot: CCL2/MCP1 Antibody - BSA Free [NBP1-07035] - Inhibition of autophagy using Atg5 siRNA aggravated foam cell formation & MCP-1 expressionHuman THP-1 macrophages were pretreated with Atg5 siRNA (20 μM) for 24 hrs, & then exposed to 80 μg/mL of ox-LDL for an additional 24 hrs. Western blot forAtg5, LC3, Beclin1, p62, & MCP-1 proteins were analyzed from the ox-LDL-stimulated THP-1 cells. beta -actin was used as loading control (A-F) & (I). THP-1 macrophage-derived foam cell formation was determined using ORO staining method (G) & (H). Scale bar: 40 μm. Bar graph indicates the mean ± SD (n = 3). *P < 0.05 & **P < 0.01 vs. NC siRNA group; #P < 0.05 & ##P < 0.01 vs. Atg5 siRNA group; &P < 0.05 & &&P < 0.01 represent significant differences between NC siRNA+ox-LDL group & Atg5 siRNA+ox-LDL group. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.17691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-07035_rabbit-polyclonal-ccl2-mcp1-antibody-31020241618266.jpg)
![Western Blot: CCL2/MCP1 Antibody - BSA Free [NBP1-07035] - Inhibition of SIRT1 using EX-527 or SIRT1 siRNA transfection enhanced MCP-1 expression & foam cell formationHuman THP-1 macrophages were pretreated with EX-527 (2 μM, for 2 hrs) or SIRT1 siRNA (20 μM, for 24 hrs), & then exposed to 80 μg/mL of ox-LDL for an additional 24 hrs. Western blot for SIRT1 & MCP-1 proteins were analyzed from the ox-LDL-stimulated THP-1 cells. beta -actin was used as loading control (A-C) & (F-H). THP-1 macrophage-derived foam cell formation was determined using ORO staining method (D-E) & (I-J). Scale bar: 40 μm. Bar graph indicates the mean ± SD (n = 3). *P < 0.05 & **P < 0.01 vs. Cont group (NC siRNA group); #P < 0.05 & ##P < 0.01 vs. EX-527 group (SIRT1 siRNA group); &P < 0.05 & &&P < 0.01 represent significant differences between ox-LDL group (NC siRNA+ox-LDL group) & EX-527+ox-LDL group (SIRT1 siRNA+ox-LDL group). Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.17691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-07035_rabbit-polyclonal-ccl2-mcp1-antibody-310202416171476.jpg)
![Western Blot: CCL2/MCP1 Antibody - BSA Free [NBP1-07035] - Overexpression of SIRT1 using adenoviral transfection reversed ox-LDL-induced macrophage foam cell formation & autophagy impairment in THP-1 cellsHuman THP-1 macrophages were transfected by SIRT1 over-expressing adenovirus (HBAD-SIRT1) or NC adenovirus (HBAD-GFP) for 24 hrs & then exposed to 80 μg/mL of ox-LDL for an additional 24 hrs. The transfected THP-1 cells were observed using an inverted fluorescence microscope (A) & then were harvested for transfection efficiency analysis by Western blot method (B). THP-1 macrophage-derived foam cell formation was determined using ORO staining method (C) & (D). Western blot for LC3, Beclin1, p62, & Atg5 proteins & immunoprecipitation for acetyl-Lys Atg5 were analyzed from the ox-LDL-stimulated THP-1 cells. beta -actin was used as loading control (E-L). Scale bar: 40 μm. Bar graph indicates the mean ± SD (n = 3). *P < 0.05 & **P < 0.01 vs. HBAD-GFP group; #P < 0.05 & ##P < 0.01 vs. HBAD-SIRT1 group; &P < 0.05 & &&P < 0.01 represent significant differences between HBAD-GFP+ox-LDL group & HBAD-SIRT1+ox-LDL group. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.17691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-07035_rabbit-polyclonal-ccl2-mcp1-antibody-310202416163742.jpg)
![Immunohistochemistry-Frozen: CD163 Antibody (EDHu-1) [NB110-40686] - Staining of a human tonsil cryosection with Mouse anti Human CD163 antibody, clone EDHu-1.](http://images.novusbio.com/fullsize/CD163-Antibody-EDHu-1-Immunohistochemistry-Frozen-NB110-40686-img0007.jpg)
![Immunohistochemistry-Paraffin: Mouse Monoclonal CD163 Antibody (EDHu-1) [NB110-40686] - CD163 immunoreactivity in a formalin fixed paraffin embedded section of canine lymph node. NB110-40686 was diluted to 0.25ug per mL and was left on the tissue section for 30m at room temperature. Section underwent 20m of heat induced epitope retrieval in a vegetable steamer using a citrate buffer. No signal was detected in sections that did not undergo HIER. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb110-40686_mouse-monoclonal-cd163-antibody-edhu-1-immunohistochemistry-paraffin-722024125639..png)
![Immunohistochemistry-Paraffin: Mouse Monoclonal CD163 Antibody (EDHu-1) [NB110-40686] - CD163 immunoreactivity in an FFPE section of human tonsil. NB110-40686 was diluted to 250 ng/mL and left on tissue sections for 30min at room temperature. Secondary was horse anti mouse HRP polymer. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb110-40686_mouse-monoclonal-cd163-antibody-edhu-1-immunohistochemistry-paraffin-294202415725..png)
![Immunohistochemistry-Paraffin: Mouse Monoclonal CD163 Antibody (EDHu-1) [NB110-40686] - CD163 immunoreactivity in an FFPE section of equine spleen. NB110-40686 was diluted to 250ng per mL and left on tissue sections for 30min at room temperature. Secondary was horse anti mouse HRP polymer. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb110-40686_mouse-monoclonal-cd163-antibody-edhu-1-immunohistochemistry-paraffin-1052024154747..jpg)
![Immunohistochemistry-Paraffin: Mouse Monoclonal CD163 Antibody (EDHu-1) [NB110-40686] - CD163 immunoreactivity in an FFPE section of feline lymph node. NB110-40686 was diluted to 250ng per mL and left on tissue sections for 30min at room temperature. Secondary was horse anti mouse HRP polymer. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb110-40686_mouse-monoclonal-cd163-antibody-edhu-1-immunohistochemistry-paraffin-105202415547..png)
![Immunocytochemistry/ Immunofluorescence: CD163 Antibody (EDHu-1) [NB110-40686] - Non-repaired & repaired VML injured muscles present sustained putative macrophage infiltration. Representative histologic images labeled with CD163 (pan macrophage marker) & wheat germ agglutinin (WGA) & DAPI (nuclei). (a) For each of the sham muscle sections individual & merged images are presented. (b) Examples for each group, specifically the non-, SIS-, UMB-, & Hya-reparied are shown. Scale bar is 150 µm; all images are at the same magnification & follow the same location pattern displayed specifically in Fig. 4e. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29030619), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-40686_mouse-monoclonal-cd163-antibody-edhu-1-31020241538410.jpg)